$TEM

Doudna Jennifer A sold $147K of TEM

Doudna Jennifer A sold 2,673 shares of Tempus AI, Inc. (TEM) at $55.00 ($0.15M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Doudna Jennifer A
Published Jun 30, 2026, 12:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosure updates the record of insider activity: a director open-market sale of 2,673 shares at $55.00/share, totaling $147,015, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 structure and lack of new fundamentals make this a low-impact datapoint.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no buy activity, and no linkage to performance or guidance—limiting interpretability.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed late June 29 (covers sale dated June 25).

Background

This is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by director Jennifer A Doudna.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI director Jennifer A Doudna sold 2,673 shares in an open-market transaction for about $147K under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.

Evidence & confidence

The filing is a director open-market sale explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying operational, financial, or regulatory change disclosed.

Market effects

Minimal; insider-sale Form 4s typically do not reset sector expectations without additional company-specific news.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish views—so any negative read-through may be overdone.

Key entities

  • Tempus AI, Inc.

    Issuer of the Form 4 insider transaction; director sale disclosed.

  • Jennifer A Doudna

    Director who sold 2,673 shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.